Mitsudomi et al reported that p53 autoantibodies were significantly more prevalent in patients with squamous cell carcinoma (27%) than in those with adenocarcinoma (15%) (p  = 0.05), while there was also a statistically significant difference in the incidence of p53 autoantibodies between the early disease group (stage I and II) (14%) and the advanced disease group (stage IIIa∼IV, 30%) (p = 0.0079) [52]. Here, TP53 is linked to adenocarcinoma.